Canaccord Reiterates Buy Rating on BridgeBio Pharma (BBIO)

October 7, 2026 6:45 AM

Canaccord analyst Whitney Ijem reiterated a Buy rating and $106.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst commented: "Yesterday ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found